Lifecore Q2 revenue $34.2M, down 6.2% YoY; net loss $6.2M vs $1.1M loss last year

LIFECORE BIOMEDICAL, INC. DE

Revenue $34.2M, down 6.2% YoY; net loss $6.2M ($0.19 loss per share) vs $1.1M loss ($0.06) in prior year.
Adjusted EBITDA $8.6M, down from $9.1M; free cash flow $0.9M for six months ended June 30, 2026.
Reaffirmed 2026 guidance; targeting 12% revenue CAGR and >25% Adjusted EBITDA margin by end of 2029.
Added 13 new programs in past 12 months, including 8 late-stage; 6 new programs signed in Q2 2026.
Ended Q2 with $38.8M liquidity ($17.2M cash, $21.6M revolver availability).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.